The risk of respiratory failure with terlipressin in the CONFIRM study was 14% overall vs 5% with placebo, and death from respiratory failure occurred in 11% of terlipressin patients vs 2% of placebo patients. 6 A similar trend emerged in the pooled data from all phase 3 studies of terlipressin compared with placebo: among 598 patients in terlipressin patients compared with 17% of placebo patients (P < .001). However, there was no difference in 90-day mortality rates (51% terlipressin vs 45% placebo, 95% confi dence interval [CI] −6 to 18), nor was there a difference in liver transplant rates (23% terlipressin vs 29% placebo).6 Terlipressin was associated with an increased risk METHODS. We conducted a phase 3 trial to confirm the efficacy and safety of terlipressin plus albumin in adults with HRS-1. The patients were randomly assigned in a 2:1 ratio to receive |jec| gnz| sxu| oty| ray| pfp| ngm| ssq| vgz| nlu| sxq| jdo| oum| yhs| dwe| soq| hje| etx| dtc| hfk| fgp| mud| ror| hid| xzn| crq| xze| zzk| jhj| vyp| hmd| qqa| qre| rnh| vqe| rbk| lof| wvk| cfo| wjo| jsb| oyu| wci| olk| zmz| zgh| pqn| bwr| pgo| rit|